Ruffer LLP Buys New Shares in LivaNova PLC (NASDAQ:LIVN)

Ruffer LLP bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, Holdings Channel reports. The firm bought 172,357 shares of the company’s stock, valued at approximately $7,982,000.

Several other institutional investors and hedge funds also recently bought and sold shares of LIVN. Point72 Asset Management L.P. lifted its position in shares of LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after acquiring an additional 806,374 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of LivaNova in the fourth quarter worth about $9,645,000. Point72 DIFC Ltd increased its stake in LivaNova by 75,799.6% during the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock worth $9,531,000 after acquiring an additional 181,161 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in LivaNova by 286.4% during the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock worth $10,889,000 after acquiring an additional 153,611 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of LivaNova by 16.6% during the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock valued at $49,130,000 after buying an additional 133,401 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Performance

NASDAQ:LIVN opened at $39.17 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a 12 month low of $38.91 and a 12 month high of $64.47. The firm has a market capitalization of $2.13 billion, a PE ratio of 93.26 and a beta of 1.10. The business’s fifty day moving average price is $46.79 and its 200 day moving average price is $49.34.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on LIVN shares. Needham & Company LLC lowered their price target on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus decreased their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Mizuho decreased their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group cut their target price on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.